Corio PSP™ – Detox RejuveNation
Amanda Pereira Silva - Patient Services Analyst Pl - Biogen | LinkedIn
Biogen on Twitter: "We'll be showcasing our work in neuroscience including the areas of multiple sclerosis (#MS), spinal muscular atrophy (#SMA), Alzheimer's Disease (#AD) and progressive supranuclear palsy (#PSP) with poster and
Medscape Neurology - After disappointing trial results, Biogen will discontinue development of gosuranemab for PSP and other primary tauopathies. http://ms.spr.ly/6182Tn3Cq | Facebook
Characteristics of patients with progressive supranuclear palsy (PSP) in US health insurance claims data Progressive supranuclea
Biogen Stock Rebounds After Impressive Q3 Earnings | InvestorPlace
PSP — Coleen Heaver
Biogen on Twitter: "Chris Henderson, VP, Neuromuscular and Movement Disorders Research Unit, highlights the importance of an early Progressive Supranuclear Palsy (PSP) diagnosis #PSPAwareness https://t.co/xDnZaZYYhT" / Twitter
What's in Biogen's Clinical Pipeline?
Biogen on Twitter: "Progressive Supranuclear Palsy (#PSP) Awareness Month may be over, but the work doesn't end here. #PSPAwareness https://t.co/oC0MNF0IVD" / Twitter
NS Innovation: la cumbre en neurociencias que cambiará la vida de millones de pacientes - Infobae
Biogen pays $300M to Bristol-Myers for another potential Alzheimer's drug - Boston Business Journal
FAQ on FDA Approval of Aducanumab - CurePSP
Carla Erba - Latam PSP Lead - Biogen | LinkedIn
Biogen | Contract Pharma
Biogen on Twitter: "#DYK…Progressive supranuclear palsy (#PSP) is a neurodegenerative disorder that affects the brain cells controlling balance, walking, coordination, eye movement, speech, swallowing and thinking. #AANAM https://t.co/uYb551MjJi" / Twitter
These Clinical Study Results are provided for informational purposes only. The study listed may include approved and non
AbbVie Discontinued a Drug Trial. Biogen Stock Is Falling. | Barron's
Biogen on Twitter: "We're dedicated to advancing research and development for movement disorders like progressive supranuclear palsy (#PSP). https://t.co/7NOueg0df4" / Twitter
Biogen y Eisai aseguran que su fármaco lecanemab frena el deterioro cognitivo en el alzhéimer | Sociedad | EL PAÍS
Acompañamos a... - Pharmexx Argentina part of Ashfield Group | Facebook
Carla Erba - Latam PSP Lead - Biogen | LinkedIn
After Recent Tau Failure, Biogen Licenses Tau Therapeutic from Ionis for Alzheimer's Disease | BioSpace
